# MountainTAP-30 (NCT07076121)

> A Study Comparing Navlimetostat (BMS-986504) in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT07076121
- Phase: PHASE2, PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Bristol-Myers Squibb
- Conditions: Pancreatic Ductal Adenocarcinoma
- Interventions: Navlimetostat; Gemcitabine; Nab-paclitaxel; Placebo
- Enrollment: 470
- Primary outcome: Progression-Free Survival as assessed by Response Evaluation Criteria in Solid Tumors version v1.1 (RECIST v1.1)
- Primary outcome: Overall Survival (OS)

## Indexed commentary on MountainTAP-30 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 3

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=mountaintap-30-nct07076121